Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Receivables (2016 - 2017)

Usana Health Sciences (USNA) has disclosed Receivables for 5 consecutive years, with $6.9 million as the latest value for Q3 2017.

  • On a quarterly basis, Receivables fell 6.9% to $6.9 million in Q3 2017 year-over-year; TTM through Jul 2017 was $6.9 million, a 6.9% decrease, with the full-year FY2016 number at $11.1 million, down 14.71% from a year prior.
  • Receivables was $6.9 million for Q3 2017 at Usana Health Sciences, up from $6.8 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $13.0 million in Q1 2016 to a low of $6.4 million in Q1 2014.
  • A 5-year average of $8.7 million and a median of $7.9 million in 2016 define the central range for Receivables.
  • Peak YoY movement for Receivables: skyrocketed 40.34% in 2015, then decreased 18.73% in 2016.
  • Usana Health Sciences' Receivables stood at $10.4 million in 2013, then fell by 29.46% to $7.4 million in 2014, then grew by 18.7% to $8.7 million in 2015, then grew by 27.35% to $11.1 million in 2016, then tumbled by 38.26% to $6.9 million in 2017.
  • Per Business Quant, the three most recent readings for USNA's Receivables are $6.9 million (Q3 2017), $6.8 million (Q2 2017), and $11.1 million (Q4 2016).